KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Change in Receivables (2016 - 2025)

Amgen has reported Change in Receivables over the past 17 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Change in Receivables at $1.1 billion for Q4 2025, up 327.27% from a year ago — trailing twelve months through Dec 2025 was $2.7 billion (up 706.8% YoY), and the annual figure for FY2025 was $2.7 billion, up 706.8%.
  • Change in Receivables for Q4 2025 was $1.1 billion at Amgen, up from -$222.0 million in the prior quarter.
  • Over the last five years, Change in Receivables for AMGN hit a ceiling of $1.3 billion in Q1 2025 and a floor of -$486.0 million in Q1 2024.
  • Median Change in Receivables over the past 5 years was $178.0 million (2022), compared with a mean of $221.2 million.
  • Biggest five-year swings in Change in Receivables: soared 451.79% in 2022 and later crashed 437.5% in 2024.
  • Amgen's Change in Receivables stood at $160.0 million in 2021, then grew by 12.5% to $180.0 million in 2022, then skyrocketed by 140.56% to $433.0 million in 2023, then crashed by 209.24% to -$473.0 million in 2024, then soared by 327.27% to $1.1 billion in 2025.
  • The last three reported values for Change in Receivables were $1.1 billion (Q4 2025), -$222.0 million (Q3 2025), and $515.0 million (Q2 2025) per Business Quant data.